{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:27:17Z","timestamp":1776310037522,"version":"3.50.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40263-025-01249-6","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T18:46:24Z","timestamp":1765565184000},"page":"451-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Effect of Psychotropic Medications on Glaucoma Risk and Intraocular Pressure: A Bayesian Meta-Analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2936-4150","authenticated-orcid":false,"given":"Tommaso B.","family":"Jannini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5366-882X","authenticated-orcid":false,"given":"Ludovico","family":"Alisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-6675","authenticated-orcid":false,"given":"Francesca","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3414-6344","authenticated-orcid":false,"given":"Marta","family":"Armentano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-4064","authenticated-orcid":false,"given":"Giorgio","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-2684","authenticated-orcid":false,"given":"Cinzia","family":"Niolu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-093X","authenticated-orcid":false,"given":"Alberto","family":"Siracusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"1249_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137. https:\/\/doi.org\/10.1136\/bjo.2005.081224.","journal-title":"Br J Ophthalmol"},{"key":"1249_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"Y-C Tham","year":"2014","unstructured":"Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013.","journal-title":"Ophthalmology"},{"key":"1249_CR3","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1038\/s41598-021-92971-w","volume":"11","author":"N Zhang","year":"2021","unstructured":"Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021;11:13762. https:\/\/doi.org\/10.1038\/s41598-021-92971-w.","journal-title":"Sci Rep"},{"key":"1249_CR4","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open-angle glaucoma preferred practice Pattern\u00ae. Ophthalmology. 2021;128:P71-150. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.022.","journal-title":"Ophthalmology"},{"key":"1249_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.preteyeres.2016.12.003","volume":"57","author":"X Sun","year":"2017","unstructured":"Sun X, Dai Y, Chen Y, Yu D-Y, Cringle SJ, Chen J, et al. Primary angle closure glaucoma: what we know and what we don\u2019t know. Prog Retin Eye Res. 2017;57:26\u201345. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.12.003.","journal-title":"Prog Retin Eye Res"},{"key":"1249_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/14656566.2022.2071124","volume":"23","author":"TB Jannini","year":"2022","unstructured":"Jannini TB, Sansone A, Rossi R, Di Lorenzo G, Toscano M, Siracusano A, et al. Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment. Expert Opin Pharmacother. 2022;23:1065\u201380. https:\/\/doi.org\/10.1080\/14656566.2022.2071124.","journal-title":"Expert Opin Pharmacother"},{"key":"1249_CR7","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"DM Taylor","year":"2025","unstructured":"Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. New York: Wiley; 2025."},{"key":"1249_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2165\/11533180-000000000-00000","volume":"24","author":"S Richa","year":"2010","unstructured":"Richa S, Yazbek J-C. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010;24:501\u201326. https:\/\/doi.org\/10.2165\/11533180-000000000-00000.","journal-title":"CNS Drugs"},{"key":"1249_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/archopht.1995.01100060020009","volume":"113","author":"M Kramer","year":"1995","unstructured":"Kramer M, Reines S. Oral imipramine and acute angle-closure glaucoma. Arch Ophthalmol Chic Ill 1960. 1995;113:698\u20139. https:\/\/doi.org\/10.1001\/archopht.1995.01100060020009.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"key":"1249_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5694\/j.1326-5377.1966.tb97299.x","volume":"2","author":"RF Lowe","year":"1966","unstructured":"Lowe RF. Amitriptyline and glaucoma. Med J Aust. 1966;2:509\u201310. https:\/\/doi.org\/10.5694\/j.1326-5377.1966.tb97299.x.","journal-title":"Med J Aust"},{"key":"1249_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s0033-3182(87)72555-9","volume":"28","author":"E Lieberman","year":"1987","unstructured":"Lieberman E, Stoudemire A. Use of tricyclic antidepressants in patients with glaucoma. Assessment and appropriate precautions. Psychosomatics. 1987;28:145\u20138. https:\/\/doi.org\/10.1016\/s0033-3182(87)72555-9.","journal-title":"Psychosomatics"},{"key":"1249_CR12","first-page":"130","volume":"21","author":"M Aragona","year":"1998","unstructured":"Aragona M, Inghilleri M. Increased ocular pressure in two patients with narrow angle glaucoma treated with venlafaxine. Clin Neuropharmacol. 1998;21:130\u20131.","journal-title":"Clin Neuropharmacol"},{"key":"1249_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/ceo.12769","volume":"44","author":"VE Botha","year":"2016","unstructured":"Botha VE, Bhikoo R, Merriman M. Venlafaxine-induced intraocular pressure rise in a patient with open angle glaucoma. Clin Experiment Ophthalmol. 2016;44:734\u20135. https:\/\/doi.org\/10.1111\/ceo.12769.","journal-title":"Clin Experiment Ophthalmol"},{"key":"1249_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1089\/jop.2017.0133","volume":"34","author":"G U\u00e7an G\u00fcnd\u00fcz","year":"2018","unstructured":"U\u00e7an G\u00fcnd\u00fcz G, Parmak Yener N, K\u0131l\u0131n\u00e7el O, G\u00fcnd\u00fcz C. How does usage of serotonin noradrenaline reuptake inhibitors affect intraocular pressure in depression patients? J Ocul Pharmacol Ther. 2018;34:354\u20139. https:\/\/doi.org\/10.1089\/jop.2017.0133.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1249_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40263-020-00790-w","volume":"35","author":"NS Jain","year":"2021","unstructured":"Jain NS, Ruan CW, Dhanji SR, Symes RJ. Psychotropic drug-induced glaucoma: a practical guide to diagnosis and management. CNS Drugs. 2021;35:283\u20139. https:\/\/doi.org\/10.1007\/s40263-020-00790-w.","journal-title":"CNS Drugs"},{"key":"1249_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132947","volume":"10","author":"AM Ciobanu","year":"2021","unstructured":"Ciobanu AM, Dionisie V, Neagu C, Bolog OM, Riga S, Popa-Velea O. Psychopharmacological treatment, intraocular pressure and the risk of glaucoma: a review of literature. J Clin Med. 2021;10:2947. https:\/\/doi.org\/10.3390\/jcm10132947.","journal-title":"J Clin Med"},{"key":"1249_CR17","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2174\/138945010791591278","volume":"11","author":"NA Sharif","year":"2010","unstructured":"Sharif NA. Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010;11:978\u201393. https:\/\/doi.org\/10.2174\/138945010791591278.","journal-title":"Curr Drug Targets"},{"key":"1249_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1124\/jpet.103.049528","volume":"306","author":"JA May","year":"2003","unstructured":"May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther. 2003;306:301\u20139. https:\/\/doi.org\/10.1124\/jpet.103.049528.","journal-title":"J Pharmacol Exp Ther"},{"key":"1249_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3758\/s13423-016-1221-4","volume":"25","author":"JK Kruschke","year":"2018","unstructured":"Kruschke JK, Liddell TM. The Bayesian new statistics: hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective. Psychon Bull Rev. 2018;25:178\u2013206. https:\/\/doi.org\/10.3758\/s13423-016-1221-4.","journal-title":"Psychon Bull Rev"},{"key":"1249_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3325\/cmj.2020.61.564","volume":"61","author":"B Hackenberger","year":"2020","unstructured":"Hackenberger B. Bayesian meta-analysis now\u2014let\u2019s do it. Croat Med J. 2020;61:564\u20138. https:\/\/doi.org\/10.3325\/cmj.2020.61.564.","journal-title":"Croat Med J"},{"key":"1249_CR21","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.ijrobp.2021.12.011","volume":"112","author":"I Fornacon-Wood","year":"2022","unstructured":"Fornacon-Wood I, Mistry H, Johnson-Hart C, Faivre-Finn C, O\u2019Connor JPB, Price GJ. Understanding the differences between Bayesian and Frequentist statistics. Int J Radiat Oncol Biol Phys. 2022;112:1076\u201382. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.12.011.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1249_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1249_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1249_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"1249_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"key":"1249_CR26","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF. What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690\u20131. https:\/\/doi.org\/10.1001\/jama.280.19.1690.","journal-title":"JAMA"},{"key":"1249_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1037\/1082-989x.7.1.105","volume":"7","author":"SB Morris","year":"2002","unstructured":"Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7:105\u201325. https:\/\/doi.org\/10.1037\/1082-989x.7.1.105.","journal-title":"Psychol Methods"},{"key":"1249_CR28","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Fran\u00e7ois R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Open Source Softw"},{"key":"1249_CR29","doi-asserted-by":"crossref","unstructured":"31. R\u00f6ver C. Bayesian random-effects meta-analysis using the bayesmeta R Package. J Stat Softw [Internet]. 2020 [cited 2025 Mar 11];93. Available from: http:\/\/www.jstatsoft.org\/v93\/i06\/.","DOI":"10.18637\/jss.v093.i06"},{"key":"1249_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3758\/s13423-017-1272-1","volume":"25","author":"JK Kruschke","year":"2018","unstructured":"Kruschke JK, Liddell TM. Bayesian data analysis for newcomers. Psychon Bull Rev. 2018;25:155\u201377. https:\/\/doi.org\/10.3758\/s13423-017-1272-1.","journal-title":"Psychon Bull Rev"},{"key":"1249_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cegh.2016.12.001","volume":"5","author":"MG Lewis","year":"2017","unstructured":"Lewis MG, Guddattu V, Kamath A, Biju S, Noronha J, Nayak B, et al. Pooling of effect estimates obtained from various study designs in systematic reviews of public health interventions: a Bayesian approach to meta-analysis. Clin Epidemiol Glob Health. 2017;5:137\u201342. https:\/\/doi.org\/10.1016\/j.cegh.2016.12.001.","journal-title":"Clin Epidemiol Glob Health"},{"key":"1249_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12874-024-02347-7","volume":"24","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Yao M, Mei F, Ma Y, Huan J, Zou K, et al. Integrating randomized controlled trials and non-randomized studies of interventions to assess the effect of rare events: a Bayesian re-analysis of two meta-analyses. BMC Med Res Methodol. 2024;24:219. https:\/\/doi.org\/10.1186\/s12874-024-02347-7.","journal-title":"BMC Med Res Methodol"},{"key":"1249_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","volume":"34","author":"RM Turner","year":"2015","unstructured":"Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JPT. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med. 2015;34:984\u201398. https:\/\/doi.org\/10.1002\/sim.6381.","journal-title":"Stat Med"},{"key":"1249_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jad.2018.07.079","volume":"241","author":"H-Y Wang","year":"2018","unstructured":"Wang H-Y, Tseng P-T, Stubbs B, Carvalho AF, Li D-J, Chen T-Y, et al. The risk of glaucoma and serotonergic antidepressants: a systematic review and meta-analysis. J Affect Disord. 2018;241:63\u201370. https:\/\/doi.org\/10.1016\/j.jad.2018.07.079.","journal-title":"J Affect Disord"},{"key":"1249_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ophtha.2003.04.004","volume":"111","author":"FW Fraunfelder","year":"2004","unstructured":"Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology. 2004;111:109\u201311. https:\/\/doi.org\/10.1016\/j.ophtha.2003.04.004.","journal-title":"Ophthalmology"},{"key":"1249_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s0002-9394(03)00774-8","volume":"137","author":"JE Craig","year":"2004","unstructured":"Craig JE, Ong TJ, Louis DL, Wells JM. Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am J Ophthalmol. 2004;137:193\u20135. https:\/\/doi.org\/10.1016\/s0002-9394(03)00774-8.","journal-title":"Am J Ophthalmol"},{"key":"1249_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.8.1108","volume":"120","author":"L Thambi","year":"2002","unstructured":"Thambi L, Kapcala LP, Chambers W, Nourjah P, Beitz J, Chen M, et al. Topiramate-associated secondary angle-closure glaucoma: a case series. Arch Ophthalmol. 2002;120:1108. https:\/\/doi.org\/10.1001\/archopht.120.8.1108.","journal-title":"Arch Ophthalmol"},{"key":"1249_CR38","unstructured":"Tobias A. Assessing the influence of a single study in the meta-anyalysis estimate. Stata Tech Bull [Internet]. StataCorp LLC; 1999 [cited 2025 Sept 19];8. https:\/\/ideas.repec.org\/\/a\/tsj\/stbull\/y1999v8i47sbe26.html. Accessed 19 Sept 2025."},{"key":"1249_CR39","doi-asserted-by":"publisher","DOI":"10.1017\/9781108975292","volume-title":"Stahl\u2019s essential psychopharmacology","author":"SM Stahl","year":"2021","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology. Cambridge: Cambridge University Press; 2021."},{"key":"1249_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1249_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00023210-200418080-00001","volume":"18","author":"C Costagliola","year":"2004","unstructured":"Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications. CNS Drugs. 2004;18:475\u201384. https:\/\/doi.org\/10.2165\/00023210-200418080-00001.","journal-title":"CNS Drugs"},{"key":"1249_CR42","doi-asserted-by":"publisher","unstructured":"European Glaucoma Society terminology and guidelines for glaucoma, 5th edition. Br J Ophthalmol. 2021;105:1\u2013169. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-egsguidelines.","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"1249_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123682","volume":"10","author":"JD Stein","year":"2015","unstructured":"Stein JD, Talwar N, Kang JH, Okereke OI, Wiggs JL, Pasquale LR. Bupropion use and risk of open-angle glaucoma among enrollees in a large U.S. managed care network. PLoS ONE. 2015;10:e0123682. https:\/\/doi.org\/10.1371\/journal.pone.0123682.","journal-title":"PLoS ONE"},{"key":"1249_CR44","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40264-020-00914-7","volume":"43","author":"WJ Kim","year":"2020","unstructured":"Kim WJ, Li J, Oh I-S, Song I, Lee E, Namkoong K, et al. Benzodiazepine use and risk of acute angle-closure glaucoma: a population-based case-crossover study. Drug Saf. 2020;43:539\u201347. https:\/\/doi.org\/10.1007\/s40264-020-00914-7.","journal-title":"Drug Saf"},{"key":"1249_CR45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ajo.2011.10.018","volume":"153","author":"M Etminan","year":"2012","unstructured":"Etminan M, Maberley D, Mikelberg FS. Use of topiramate and risk of glaucoma: a case\u2013control study. Am J Ophthalmol. 2012;153:827\u201330. https:\/\/doi.org\/10.1016\/j.ajo.2011.10.018.","journal-title":"Am J Ophthalmol"},{"key":"1249_CR46","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1038\/s41433-024-03100-6","volume":"38","author":"R Darwich","year":"2024","unstructured":"Darwich R, Etminan M, He B, Eadie BD. Medications for attention deficit hyperactivity disorder associated with increased risk of developing glaucoma. Eye. 2024;38:2638\u201343. https:\/\/doi.org\/10.1038\/s41433-024-03100-6.","journal-title":"Eye"},{"key":"1249_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.7013","volume":"327","author":"CM Mangione","year":"2022","unstructured":"US Preventive Services Task Force, Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, et al. Screening for primary open-angle glaucoma: US Preventive Services Task Force recommendation statement. JAMA. 2022;327:1992. https:\/\/doi.org\/10.1001\/jama.2022.7013.","journal-title":"JAMA"},{"key":"1249_CR48","unstructured":"Overview | Glaucoma: diagnosis and management | Guidance | NICE [Internet]. [cited 2025 Sept 19]. https:\/\/www.nice.org.uk\/guidance\/ng81. Accessed 19 Sept 2025."},{"key":"1249_CR49","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta11410","volume":"11","author":"JM Burr","year":"2007","unstructured":"Burr JM, Mowatt G, Hern\u00e1ndez R, Siddiqui MaR, Cook J, Lourenco T, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii\u2013iv, ix\u2013x, 1\u2013190. https:\/\/doi.org\/10.3310\/hta11410.","journal-title":"Health Technol Assess"},{"key":"1249_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/IJG.0000000000002132","volume":"32","author":"A Anton","year":"2023","unstructured":"Anton A, Serrano D, Nolivos K, Fatti G, Zmuc N, Crespo C, et al. Cost-effectiveness of screening for open angle glaucoma compared with opportunistic case finding. J Glaucoma. 2023;32:72\u20139. https:\/\/doi.org\/10.1097\/IJG.0000000000002132.","journal-title":"J Glaucoma"},{"key":"1249_CR51","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jval.2025.06.006","volume":"28","author":"B-J Boverhof","year":"2025","unstructured":"Boverhof B-J, Corro Ramos I, Vermeer KA, de Vries VA, Klaver CCW, Ramdas WD, et al. The cost-effectiveness of an artificial intelligence-based population-wide screening program for primary open-angle glaucoma in The Netherlands. Value Health. 2025;28:1317\u201326. https:\/\/doi.org\/10.1016\/j.jval.2025.06.006.","journal-title":"Value Health"},{"key":"1249_CR52","unstructured":"Are glaucoma screenings covered by Medicare? [Internet]. [cited 2025 Sept 19]. https:\/\/www.uhc.com\/news-articles\/medicare-articles\/are-glaucoma-screenings-covered-by-medicare. Accessed 19 Sept 2025."},{"key":"1249_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0079-6123(08)01104-7","volume":"173","author":"N Amerasinghe","year":"2008","unstructured":"Amerasinghe N, Aung T. Angle-closure: risk factors, diagnosis and treatment. Prog Brain Res. 2008;173:31\u201345. https:\/\/doi.org\/10.1016\/S0079-6123(08)01104-7.","journal-title":"Prog Brain Res"},{"key":"1249_CR54","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.4103\/ijo.IJO_2134_21","volume":"70","author":"AM Al Owaifeer","year":"2022","unstructured":"Al Owaifeer AM, AlSultan ZM, Badawi AH. Topiramate-induced acute angle closure: a systematic review of case reports and case series. Indian J Ophthalmol. 2022;70:1491\u2013501. https:\/\/doi.org\/10.4103\/ijo.IJO_2134_21.","journal-title":"Indian J Ophthalmol"},{"key":"1249_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychores.2019.04.013","volume":"122","author":"MY Park","year":"2019","unstructured":"Park MY, Kim WJ, Lee E, Kim C, Son SJ, Yoon JS, et al. Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: a population-based study. J Psychosom Res. 2019;122:1\u20135. https:\/\/doi.org\/10.1016\/j.jpsychores.2019.04.013.","journal-title":"J Psychosom Res"},{"key":"1249_CR56","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","volume":"130","author":"JE Vergroesen","year":"2023","unstructured":"Vergroesen JE, Schuster AK, Stuart KV, Asefa NG, Cougnard-Gr\u00e9goire A, Delcourt C, et al. Association of systemic medication use with glaucoma and intraocular pressure: the European Eye Epidemiology Consortium. Ophthalmology. 2023;130:893\u2013906. https:\/\/doi.org\/10.1016\/j.ophtha.2023.05.001.","journal-title":"Ophthalmology"},{"key":"1249_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173005","volume":"12","author":"VC-H Chen","year":"2017","unstructured":"Chen VC-H, Ng M-H, Chiu W-C, McIntyre RS, Lee Y, Lin T-Y, et al. Effects of selective serotonin reuptake inhibitors on glaucoma: a nationwide population-based study. PLoS ONE. 2017;12:e0173005. https:\/\/doi.org\/10.1371\/journal.pone.0173005.","journal-title":"PLoS ONE"},{"key":"1249_CR58","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10038","volume":"77","author":"H-Y Chen","year":"2016","unstructured":"Chen H-Y, Lin C-L, Lai S-W, Kao C-H. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016;77:e692-696. https:\/\/doi.org\/10.4088\/JCP.15m10038.","journal-title":"J Clin Psychiatry"},{"key":"1249_CR59","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_2804_24","volume":"73","author":"G Behera","year":"2025","unstructured":"Behera G, Lenin J, Bharadwaj B, Mahalingam K, Ram A, Natarajan K, et al. Comparing the effect of sympathomimetic\/anticholinergic psychotropic drugs with that of non-sympathomimetic\/anticholinergic psychotropic drugs on IOP and angle parameters among patients on long-term therapy. Indian J Ophthalmol. 2025;73:S454\u20139. https:\/\/doi.org\/10.4103\/IJO.IJO_2804_24.","journal-title":"Indian J Ophthalmol"},{"key":"1249_CR60","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1177\/1060028014529645","volume":"48","author":"AS Shifera","year":"2014","unstructured":"Shifera AS, Leoncavallo A, Sherwood M. Probable association of an attack of bilateral acute angle-closure glaucoma with duloxetine. Ann Pharmacother. 2014;48:936\u20139. https:\/\/doi.org\/10.1177\/1060028014529645.","journal-title":"Ann Pharmacother"},{"key":"1249_CR61","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/bjo.2006.107185","volume":"91","author":"P Massaoutis","year":"2007","unstructured":"Massaoutis P, Goh D, Foster PJ. Bilateral symptomatic angle closure associated with a regular dose of citalopram, an SSRI antidepressant. Br J Ophthalmol. 2007;91:1086\u20137. https:\/\/doi.org\/10.1136\/bjo.2006.107185.","journal-title":"Br J Ophthalmol"},{"key":"1249_CR62","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/IJG.0000000000001378","volume":"28","author":"H Zhang","year":"2019","unstructured":"Zhang H, Jia H, Duan X, Li L, Wang H, Wu J, et al. The Chinese glaucoma study consortium for patients with glaucoma: design, rationale and baseline patient characteristics. J Glaucoma. 2019;28:974\u20138. https:\/\/doi.org\/10.1097\/IJG.0000000000001378.","journal-title":"J Glaucoma"},{"key":"1249_CR63","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.2147\/OPTH.S536664","volume":"19","author":"JS Myers","year":"2025","unstructured":"Myers JS, Donckels EA, Davis TH, Robinson SB, Pulungan Z, Brevetti TL, et al. Prevalence, incidence, and treatment characteristics of primary open-angle glaucoma among medicare fee-for-service beneficiaries. Clin Ophthalmol Auckl NZ. 2025;19:3019\u201331. https:\/\/doi.org\/10.2147\/OPTH.S536664.","journal-title":"Clin Ophthalmol Auckl NZ."},{"key":"1249_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2023.2264387","author":"GL Qiao","year":"2024","unstructured":"Qiao GL, Mikelberg FS, Etminan M, Taylor & Francis. Use of diuretics and risk of acute angle closure: a case-control study. Ophthalmic Epidemiol. 2024. https:\/\/doi.org\/10.1080\/09286586.2023.2264387.","journal-title":"Ophthalmic Epidemiol"},{"key":"1249_CR65","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/jamaophthalmol.2022.3723","volume":"140","author":"KI Na","year":"2022","unstructured":"Na KI, Park SP. Association of drugs with acute angle closure. JAMA Ophthalmol. 2022;140:1055\u201363. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3723.","journal-title":"JAMA Ophthalmol"},{"key":"1249_CR66","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10792-022-02396-1","volume":"43","author":"MA \u00d6zer","year":"2023","unstructured":"\u00d6zer MA, Sar\u0131 \u0130F, Ko\u00e7 H, Yavuz N\u00c7, \u00d6zen S, Kulakl\u0131 F. Evaluation of the effects of duloxetine treatment on anterior segment parameters by optical coherence tomography. Int Ophthalmol. 2023;43:141\u20136. https:\/\/doi.org\/10.1007\/s10792-022-02396-1.","journal-title":"Int Ophthalmol"},{"key":"1249_CR67","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/24750573.2019.1673944","volume":"29","author":"Y Karak\u00fc\u00e7\u00fck","year":"2019","unstructured":"Karak\u00fc\u00e7\u00fck Y, Beyoglu A, \u00c7\u00f6mez A, Orhan F\u00d6, Demir M. Early effects of selective serotonin reuptake inhibitors (SSRIs) on cornea and lens density in patients with depression. Psychiatry Clin Psychopharmacol. 2019;29:387\u201393. https:\/\/doi.org\/10.1080\/24750573.2019.1673944.","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"1249_CR68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/15569527.2017.1330270","volume":"37","author":"GU G\u00fcnd\u00fcz","year":"2018","unstructured":"G\u00fcnd\u00fcz GU, Parmak Yener N, K\u0131l\u0131n\u00e7el O, G\u00fcnd\u00fcz C. Effects of selective serotonin reuptake inhibitors on intraocular pressure and anterior segment parameters in open angle eyes. Cutan Ocul Toxicol. 2018;37:36\u201340. https:\/\/doi.org\/10.1080\/15569527.2017.1330270.","journal-title":"Cutan Ocul Toxicol"},{"key":"1249_CR69","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.ophtha.2018.01.007","volume":"125","author":"W Zheng","year":"2018","unstructured":"Zheng W, Dryja TP, Wei Z, Song D, Tian H, Kahler KH, et al. Systemic medication associations with presumed advanced or uncontrolled primary open-angle glaucoma. Ophthalmology. 2018;125:984\u201393. https:\/\/doi.org\/10.1016\/j.ophtha.2018.01.007.","journal-title":"Ophthalmology"},{"key":"1249_CR70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/bjophthalmol-2016-308846","volume":"101","author":"M Mas\u00eds","year":"2017","unstructured":"Mas\u00eds M, Kakigi C, Singh K, Lin S. Association between self-reported bupropion use and glaucoma: a population-based study. Br J Ophthalmol. 2017;101:525\u20139. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308846.","journal-title":"Br J Ophthalmol"},{"key":"1249_CR71","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002041","volume":"94","author":"H-Y Chen","year":"2015","unstructured":"Chen H-Y, Lin C-L, Kao C-H. Long-term use of selective serotonin reuptake inhibitors and risk of glaucoma in depression patients. Medicine (Baltimore). 2015;94:e2041. https:\/\/doi.org\/10.1097\/MD.0000000000002041.","journal-title":"Medicine (Baltimore)"},{"key":"1249_CR72","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaophthalmol.2015.2180","volume":"133","author":"RJ Symes","year":"2015","unstructured":"Symes RJ, Etminan M, Mikelberg FS. Risk of angle-closure glaucoma with bupropion and topiramate. JAMA Ophthalmol. 2015;133:1187\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.2180.","journal-title":"JAMA Ophthalmol"},{"key":"1249_CR73","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/JCP.0b013e31825420a1","volume":"32","author":"DP Seitz","year":"2012","unstructured":"Seitz DP, Campbell RJ, Bell CM, Gill SS, Gruneir A, Herrmann N, et al. Short-term exposure to antidepressant drugs and risk of acute angle-closure glaucoma among older adults. J Clin Psychopharmacol. 2012;32:403\u20137. https:\/\/doi.org\/10.1097\/JCP.0b013e31825420a1.","journal-title":"J Clin Psychopharmacol"},{"key":"1249_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2188\/jea.JE20140051","volume":"25","author":"Y-H Ho","year":"2015","unstructured":"Ho Y-H, Chang Y-C, Huang W-C, Chen H-Y, Lin C-C, Sung F-C. Association between zolpidem use and glaucoma risk: a Taiwanese population-based case-control study. J Epidemiol. 2015;25:15\u20139. https:\/\/doi.org\/10.2188\/jea.JE20140051.","journal-title":"J Epidemiol"},{"key":"1249_CR75","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ajo.2012.07.016","volume":"155","author":"J-D Ho","year":"2013","unstructured":"Ho J-D, Keller JJ, Tsai C-Y, Liou S-W, Chang C-J, Lin H-C. Topiramate use and the risk of glaucoma development: a population-based follow-up study. Am J Ophthalmol. 2013;155:336-341.e1. https:\/\/doi.org\/10.1016\/j.ajo.2012.07.016.","journal-title":"Am J Ophthalmol"},{"key":"1249_CR76","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jaapos.2015.04.005","volume":"19","author":"P Larra\u00f1aga-Fragoso","year":"2015","unstructured":"Larra\u00f1aga-Fragoso P, Noval S, Rivero JC, Boto-de-los-Bueis A. The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder. J Am Assoc Pediatr Ophthalmol Strabismus. 2015;19:322\u20136. https:\/\/doi.org\/10.1016\/j.jaapos.2015.04.005.","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"1249_CR77","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.15586\/jptcp.v27i2.665","volume":"27","author":"O Guvenmez","year":"2020","unstructured":"Guvenmez O, Cubuk M, Gunes S. The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: a prospective study. J Popul Ther Clin Pharmacol. 2020;27:e45-50. https:\/\/doi.org\/10.15586\/jptcp.v27i2.665.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"1249_CR78","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.4103\/ijo.IJO_2966_21","volume":"70","author":"P Bing\u00f6l-K\u0131z\u0131ltun\u00e7","year":"2022","unstructured":"Bing\u00f6l-K\u0131z\u0131ltun\u00e7 P, Y\u00fcr\u00fcmez E, Atilla H. Does methylphenidate treatment affect functional and structural ocular parameters in patients with attention deficit hyperactivity disorder?\u2014A prospective, one year follow-up study. Indian J Ophthalmol. 2022;70:1664\u20138. https:\/\/doi.org\/10.4103\/ijo.IJO_2966_21.","journal-title":"Indian J Ophthalmol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01249-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01249-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:03:18Z","timestamp":1771430598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01249-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01249-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"T.B.J., L.A., M.A., and F.G. conceived the study and performed the literature search and data extraction. G.D.L. and C.N. contributed to the statistical analysis and interpretation of data. A.S. provided critical revisions and expert guidance throughout the project. All authors (L.A., M.A., F.G., T.B.J., G.D.L., C.N., and A.S.) contributed to drafting or revising the manuscript for important intellectual content. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}